TLSI — TriSalus Life Sciences, Inc.

Summary of TriSalus Life Sciences Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $11.6 million, a 57% increase year-over-year and a 3% sequential gain from Q2 2025.
• Gross Margin: 84%, down from 86% in the prior year, attributed to lower manufacturing efficiency with new product launches.
• Operating Loss: $9 million, slightly higher than $8.7 million in Q3 2024, impacted by a one-time charge related to clinical study closures.
• Cash Used in Operations: $3.7 million, significantly improved from $11.2 million in Q3 2024.
• Adjusted EBITDA Loss: $5.4 million, an improvement from $7.1 million in the prior year.
• Cash and Cash Equivalents: $22.7 million at quarter-end, with a reduced minimum cash covenant from $10 million to $5 million post-debt amendment.

2. Strategic Updates and Business Highlights

• Launched the TriNav FLX infusion system, expanding the TriNav platform and advancing clinical applications.
• Increased commercial investment to support growth, extending the timeline to reach EBITDA positive and cash flow breakeven.
• Expanded the addressable market through new applications, including uterine artery embolization and genicular artery embolization.
• Positive feedback from early evaluations of the next-generation TriNav XP, enhancing treatment capabilities for complex cases.
• Continued enrollment in the PROTECT registry for PEDD technology in thyroid nodules, showing promising preliminary results.

3. Forward Guidance and Outlook

• Reaffirmed guidance for 50% revenue growth for the year, reflecting confidence in commercial momentum and market opportunities.
• Anticipated adjusted EBITDA positivity in the first half of 2026.
• Focus on expanding the clinical utility of TriNav and advancing partnerships for nelitolimod to reduce development costs.

4. Bad News, Challenges, or Points of Concern

• Gross margin decline due to manufacturing inefficiencies with new product launches, expected to stabilize in Q4.
• Increased operating expenses, particularly in R&D and G&A, driven by one-time charges and accelerated stock-based compensation.
• Challenges in educating physicians on new reimbursement codes, which may slow adoption rates for new applications.

5. Notable Q&A Insights

• Management refrained from providing specific guidance for 2026 but expressed confidence in current momentum and growth potential.
• Mapping procedures are estimated to contribute about 30% of growth, with ongoing education needed for broader adoption.
• The competitive landscape for genicular artery embolization is evolving, with TriNav positioned to offer advantages in drug delivery precision.
• Utilization rates are improving as physicians become more familiar with TriNav technology, with a notable increase in account penetration and user adoption.

Overall, TriSalus Life Sciences reported strong growth in Q3 2025, driven by strategic investments and product launches, while also facing challenges related to operational efficiency and market education. The company remains optimistic about future growth and expanding its market presence.